Arovella Therapeutics (ALA) H2 2025 earnings summary

Executive summary

• Revenue increased 700% year-over-year to $136,000, while net loss after tax narrowed by 14.1% to $7,509,166 compared to the prior year.

• Net assets rose to $20.1 million, supported by a $15 million share placement completed in March 2025.

• The company advanced its iNKT cell platform, progressing lead product ALA-101 toward a first-in-human phase 1 clinical trial for CD19-positive blood cancers.

• Expanded pipeline with new technologies and partnerships, including options for additional CARs from Baylor College of Medicine and research agreements with UNC.

Financial highlights

• Revenue: $136,000 (up from $17,000 in FY24).

• Net loss after tax: $7,509,166 (improved from $8,746,035 in FY24).

• R&D tax incentive income: $3,303,264 (up from $1,935,122 in FY24).

• Cash and cash equivalents: $20,877,185 (up from $12,714,407 in FY24).

• Net tangible assets per share: 1.69 cents (up from 1.07 cents in FY24).

Outlook and guidance

• Well-funded to complete enrolment in the phase 1 trial for ALA-101.

• Plans to expedite development of additional pipeline products following IND acceptance for ALA-101.

• Continued focus on expanding the iNKT cell platform and leveraging regulatory pathways for faster approval and market exclusivity.